You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 14, 2024

CLINICAL TRIALS PROFILE FOR SOMAVERT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Somavert

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00151437 ↗ Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed Pfizer Phase 4 2004-11-01 The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
NCT00476879 ↗ Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content Completed Aarhus University Hospital N/A 2006-08-01 The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00476879 ↗ Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content Completed Pfizer N/A 2006-08-01 The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00476879 ↗ Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content Completed University of Aarhus N/A 2006-08-01 The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00552851 ↗ Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status Pfizer Phase 4 2006-06-01 The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.
NCT00552851 ↗ Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status University of Wuerzburg Phase 4 2006-06-01 The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.
NCT00652379 ↗ Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients Completed Aarhus University Hospital N/A 2008-06-01 The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy. Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Somavert

Condition Name

Condition Name for Somavert
Intervention Trials
Acromegaly 9
Insulin Resistance 2
Lung Neoplasms 1
Adults Growth Hormone Deficiency. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Somavert
Intervention Trials
Acromegaly 9
Insulin Resistance 2
Colorectal Neoplasms 1
Endocrine System Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Somavert

Trials by Country

Trials by Country for Somavert
Location Trials
Canada 8
United States 6
Denmark 3
Germany 2
Poland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Somavert
Location Trials
California 3
Oregon 1
Tennessee 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Somavert

Clinical Trial Phase

Clinical Trial Phase for Somavert
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Somavert
Clinical Trial Phase Trials
Completed 9
Unknown status 3
Terminated 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Somavert

Sponsor Name

Sponsor Name for Somavert
Sponsor Trials
Pfizer 5
Aarhus University Hospital 3
University of Aarhus 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Somavert
Sponsor Trials
Other 19
Industry 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.